The effect of topical minoxidil plus betamethasone on androgenetic alopecia

Randomized Clinical Trial Comparing 5% Topical Minoxidil and 5% Topical Minoxidil plus Topical Betamethasone for the Treatment of Androgenetic Alopecia in Iranian Men

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016031727095N1

Enrollment

Registered

2016-05-24

Start date

2016-04-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenetic Alopecia. male-pattern baldness

Interventions

Intervention 1: In the first visit we will take a biopsy specimen from scalp for routine histopathological studies. A 2*2 centimeters area of scalp will be photographed by a trichoscope for the purpos

Treatment - Drugs

In the first visit we will take a biopsy specimen from scalp for routine histopathological studies. A 2*2 centimeters area of scalp will be photographed by a trichoscope for the purpose of counting. T

Eligibility

Sex/Gender

Male

Age

25 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Androgenetic alopecia; Age 25 and more; Age less than 40 Exclusion criteria: using of corticosteroids; NSAIDs; Cytotoxic agents; topical antiseptics and anti fungals; vasodilators; antibiotics; anti hypertensive medications; diuretics; spirnolactone; cimetidine; cyclosporin; finasteride; ketoconazole

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hair growing. Timepoint: 2 months. Method of measurement: Trichoscopy.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mehdi Gheysari

Shahid Beheshti University of Medical Sciences and Health Services

arash.bagheri@gmail.com+98 21 5541 9005

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026